Stem cell therapy may free Type 1 diabetes patients from insulin
A clinical trial published in NEJM shows stem cell-based ‘living pharmacy’ treatment may eliminate the need for daily insulin in Type 1 diabetes patients. Most participants achieved insulin independence, though challenges like immune rejection still remain.
Hyderabad: A clinical trial published in the New England Journal of Medicine (NEJM) has set the medical world buzzing, with results indicating that stem cell treatment has the potential to replace daily insulin injections in Type 1 diabetes patients.
Signalling a major shift in Type 1 diabetes treatment, the study demonstrated that lab-grown ‘living pharmacy’ cells can effectively replace daily insulin injections.
For the millions living with the autoimmune condition globally, the results of this early-stage trial represent more than just a breakthrough; they offer a potential path to a functional cure.
The study followed twelve participants whose immune systems had destroyed their natural insulin-producing islet cells.
Researchers infused the study participants with specialised stem cells engineered to behave like a healthy pancreas. Unlike traditional treatments that require external monitoring, these “smart” cells sense blood glucose levels in real time and secrete precise amounts of insulin.
According to the results, 10 out of 12 participants achieved total insulin independence within one year. The remaining two participants saw their exogenous insulin requirements drop significantly. The transplanted cells successfully integrated into the patients’ systems, mimicking the dynamic glucose control of a non-diabetic individual.
While the results are transformative, the body’s immune system continues to pose significant challenges. Since these lab-grown cells are foreign, trial participants must currently take lifelong immunosuppressive drugs to prevent rejection.
Scientists are currently testing ‘cloaking’ technologies and CRISPR gene editing to create ‘hypoimmune’ cells that can evade the body’s defences, potentially eliminating the need for anti-rejection medication altogether.
For patients and families, this trial shows that freedom from the gruelling routine of finger pricks and pumps is no longer a distant dream, but a clinical reality moving rapidly towards the mainstream.
